Eli Lilly (LLY) Delivers +48% Revenue Growth While Novartis (NVS) Manages Transition
Key Takeaways
- Eli Lilly (LLY) is delivering roughly 48% year-over-year revenue growth, driven by its obesity and diabetes franchise, while Novartis (NVS) is growing in the low single digits as it absorbs patent expiries.
- LLY trades at a substantial valuation premium (a price-to-earnings ratio around 38x) versus NVS (around 21x), reflecting very different growth profiles.
- NVS has been hit by two late-stage clinical trial failures in recent weeks, while LLY reported positive results across three Phase 3 trials for its next-generation weight-loss drug.
- LLY offers minimal dividend income (under 1% yield), whereas NVS provides a more defensive profile with a dividend yield above 3%.
- Analyst consensus on LLY skews strongly toward "Buy," while NVS carries a more cautious "Hold" consensus.
Why These Two Pharma Names Stand Apart
Pharmaceutical stocks rarely move in lockstep, and the gap between Eli Lilly and Company (LLY) and Novartis AG (NVS) shows how sharply two large-cap drugmakers can diverge. One is riding a historic wave of demand for metabolic medicines; the other is managing a pipeline transition amid patent cliffs and recent clinical setbacks. This comparison matters for growth-oriented investors weighing momentum and valuation, as well as income-focused investors assessing stability and yield. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
LLY’s Momentum in Metabolic Therapies
Eli Lilly and Company is an Indiana-based pharmaceutical leader whose fortunes have become closely tied to incretin medicines, including GLP-1 therapies such as Mounjaro and Zepbound. In its most recent quarter, the company posted revenue of about $22.97 billion, up roughly 48% year over year and well above consensus, with combined Mounjaro and Zepbound sales reaching approximately $14.9 billion. Management raised full-year revenue guidance to a range of $85–$87 billion.
Recent market activity has reflected a mix of strength and profit-taking. The stock pulled back about 8% from recent highs after a prolonged advance, even as analysts maintained broadly bullish targets. Key catalysts include positive late-stage results for retatrutide, an investigational next-generation weight-loss therapy, and the ongoing U.S. launch of Foundayo. The main emerging concern has shifted from supply constraints to pricing, as U.S. realized prices eased modestly even while volume growth accelerated. From what I see, the earnings trajectory remains compelling.
NVS Navigating Patent Losses and Pipeline Setbacks
Novartis AG is a Swiss pharmaceutical company whose shares trade in the U.S. as an ADR. It concentrates on oncology, immunology, neuroscience, and cardiovascular-renal-metabolic medicine. Unlike LLY’s rapid expansion, NVS has been working through the loss of exclusivity on blockbuster drugs such as Entresto, whose U.S. sales have fallen sharply due to generic competition.
The company returned to growth in its most recent quarter, with sales up about 1% in constant currency, and its newer growth drivers—including Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix—rising roughly 36%. However, sentiment has been pressured by two late-stage trial failures in a single recent week: pelacarsen in cardiovascular disease and del-desiran in myotonic dystrophy. The latter triggered one of the stock’s sharpest single-day declines in two decades. On the positive side, remibrutinib posted favorable results in multiple sclerosis trials and secured new regulatory approvals, and the company continues to pay a substantial dividend. I’m watching this closely because the near-term volatility could create opportunities for patient investors.
Valuation, Yield, and Risk Trade-Offs
The contrast between these two companies is primarily a contrast between growth and transition. LLY’s business model is heavily concentrated in a fast-expanding cardiometabolic franchise, giving it exceptional revenue momentum but also exposure to pricing scrutiny and competition in the obesity market. NVS, by contrast, operates a more diversified portfolio across multiple therapeutic areas, which provides balance but has recently been undermined by generic erosion and pipeline setbacks.
On valuation, LLY trades near 38x trailing earnings versus roughly 21x for NVS—a reflection of LLY’s far stronger earnings trajectory. Dividend investors face a clear trade-off: LLY yields under 1%, while NVS offers a yield above 3%, supported by consistent buybacks and capital returns. Momentum also diverges sharply; LLY has posted a strong 52-week gain, whereas NVS has been essentially flat year-to-date amid trial failures and an activist investor’s call for governance changes. Risk profiles differ as well: LLY’s risk centers on valuation and pricing, while NVS faces execution risk tied to pipeline readouts and deal strategy.
AI-Assisted Perspective on Relative Strength
Based on observable factors—trend consistency, relative momentum, earnings revision strength, and the balance of near-term catalysts—Tickeron’s AI would currently lean toward LLY. The stock’s sustained uptrend, accelerating revenue growth, upward earnings revisions, and a pipeline of late-stage catalysts present a more favorable pattern for trend-following and momentum-oriented models. NVS, while offering stability and income, has exhibited weaker trend signals and greater recent volatility following clinical setbacks. That said, the verdict is probabilistic rather than definitive: valuation risk in LLY and the potential for positive NVS catalysts could shift the relative ranking as new data emerges.
Exploring AI Trading Strategies
When comparing names like these, I sometimes look at Tickeron’s Trending AI Robots to see which automated strategies are performing well in the current environment. The page highlights bots with strong recent results across different tickers and timeframes, helping users identify approaches that align with prevailing market conditions without having to review the entire catalog. It provides a practical way to test ideas alongside traditional analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NVS's RSI Oscillator recovers from oversold territory
The RSI Indicator for NVS moved out of oversold territory on September 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 14 of the 24 cases the stock moved higher. This puts the odds of a move higher at 58%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 31 of 54 cases where NVS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for NVS just turned positive on September 24, 2026. Looking at past instances where NVS's MACD turned positive, the stock continued to rise in 26 of 46 cases over the following month. The odds of a continued upward trend are 57%.
Following a +2.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 182 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVS as a result. In 42 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 51%.
NVS moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NVS crossed bearishly below the 50-day moving average on September 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 38%.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
NVS broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.720) is normal, around the industry mean (19.199). P/E Ratio (22.187) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). Dividend Yield (0.032) settles around the average of (0.025) among similar stocks. P/S Ratio (4.715) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care and nutritional products
Industry PharmaceuticalsMajor
Advertisement